Related Experiment Videos
Different handling of beta 2-microglobulin during hemodialysis and hemofiltration
J P Kaiser1, J Hagemann, D von Herrath
1Medizinische Abteilung II, St.-Joseph-Krankenhaus, Berlin.
Abstract:
Very recently it was reported that the amyloid associated with chronic hemodialysis contains, as a major component, a new form of amyloid fibril protein which is homologous to beta 2-microglobulin. As beta 2-microglobulin has a molecular weight of 11,600 daltons, investigations were carried out to see whether or not this protein would be handled differently by hemodialysis and hemofiltration, because the latter method especially is capable of eliminating solutes with such a high molecular weight. The results clearly indicate that hemofiltration removes substantial amounts of beta 2-microglobulin (about 190 mg per treatment, which represents 80% of daily production). It remains to be clarified whether or not hemofiltration is therefore superior to hemodialysis with regard to amyloid deposit formation.
Insights
Hemofiltration effectively removes beta 2-microglobulin, a protein linked to amyloid deposits in dialysis patients. Further research is needed to determine if this method prevents amyloid formation better than hemodialysis.
Area of Science:
- Nephrology
- Biochemistry
- Materials Science
Background:
- Amyloid deposits in chronic hemodialysis patients are primarily composed of a novel amyloid fibril protein homologous to beta 2-microglobulin.
- Beta 2-microglobulin has a molecular weight of 11,600 daltons, influencing its removal by different dialysis techniques.
Purpose of the Study:
- To investigate the differential handling of beta 2-microglobulin by hemodialysis and hemofiltration.
- To assess the efficacy of hemofiltration in removing beta 2-microglobulin due to its high molecular weight.
Main Methods:
- Comparative analysis of solute removal during hemodialysis and hemofiltration.
- Quantification of beta 2-microglobulin levels before and after treatment.
Main Results:
- Hemofiltration demonstrated substantial removal of beta 2-microglobulin, averaging approximately 190 mg per treatment.
- This removal represents about 80% of the estimated daily production of beta 2-microglobulin.
Conclusions:
- Hemofiltration effectively clears beta 2-microglobulin, a key component of dialysis-associated amyloid.
- The clinical significance of hemofiltration in preventing beta 2-microglobulin amyloidosis requires further investigation compared to hemodialysis.